Completed

Pharmacokinetics of Antituberculosis Agents in HIV-Infected Persons With Tuberculosis

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Blood-Borne Infections+21

+ Urogenital Diseases

+ Genital Diseases

Over 13 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Patients receive up to 8 weeks of two or more anti-tuberculosis drugs, of which at least two are isoniazid, rifampin, pyrazinamide, or ethambutol. Blood specimens are collected at 2, 6, and 10 hours after administration of study medication, once between Days 10 and 14 of a phase of daily treatment and once while on an intermittent dose regimen (twice weekly or three times weekly).

Official TitlePharmacokinetics of Antituberculosis Agents in HIV-Infected Persons With Tuberculosis
NCT00000950
Principal SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

50 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 13 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesAcquired Immunodeficiency SyndromeActinomycetales InfectionsBacterial Infections and MycosesBacterial InfectionsCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsMycobacterium InfectionsOpportunistic InfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesTuberculosisVirus DiseasesSexually Transmitted Diseases, ViralHIV InfectionsLentivirus InfectionsGram-Positive Bacterial InfectionsAIDS-Related Opportunistic Infections

Criteria

Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive and have tuberculosis. * Are 13 years of age or older. * Have written, informed consent of parent or guardian if you are under 18 years of age. * Agree to practice abstinence or use barrier methods of birth control during the study. Exclusion Criteria You will not be eligible for this study if you: * Have any other disorder or condition which might cause study treatment to be undesirable. * Are pregnant.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 13 locations

Suspended

Univ of Southern California / LA County USC Med Ctr

Los Angeles, United StatesOpen Univ of Southern California / LA County USC Med Ctr in Google Maps
Suspended

Harbor UCLA Med Ctr

Torrance, United States
Suspended

University of Miami (Pediatric)

Miami, United States
Suspended

Emory Univ

Atlanta, United States
Completed13 Study Centers